Skip to main content

Table 3 Prospective associations of plasma tran-fatty acids with risk of cardiovascular diseases mortality (n = 1456)

From: Plasma trans-fatty acids levels and mortality: a cohort study based on 1999–2000 National Health and Nutrition Examination Survey (NHANES)

  Events (n/%) Number at risk (Person-years) Model 1 Model 2 Model 3
Hazard Ratio
(95% CI)
P value Hazard Ratio
(95% CI)
P value Hazard Ratio
(95% CI)
P value
Elaidic acid (C18:1 t9), μM
Per 10 units increase 39(2.7) 1456 (16034) 1.14(1.02–1.27) 0.021 1.12(0.95–1.33) 0.180 1.64(1.07–2.50) 0.023
Per sd increase 1.33(1.04–1.69) 0.021 1.29(0.89–1.88) 0.180 2.96(1.16–7.55) 0.023
Quartile (Range, μM)
 Quartile 1 (4.5–23.4) 6(1.7) 363(3974) 0.66(0.24–1.81) 0.415 1.01(0.34–3.01) 0.983 0.99(0.33–3.04) 0.993
 Quartile 2 (23.5–32.3) 10(2.8) 363(4078) Reference   Reference   Reference  
 Quartile 3 (32.4–44.7) 11(3.0) 366(4048) 1.34(0.56–3.18) 0.512 1.31(0.53–3.23) 0.562 1.44(0.56–3.68) 0.447
 Quartile 4 (44.9–238) 12(3.3) 364(3934) 1.36(0.58–3.18) 0.473 1.34(0.48–3.71) 0.572 1.67(0.50–5.61) 0.404
Vaccenic acid (C18:1 t11), μM
Per 10 units increase 39(2.7) 1456 (16034) 1.08(0.98–1.18) 0.135 1.04(0.90–1.20) 0.621 0.75(0.52–1.09) 0.134
Per sd increase 1.20(0.94–1.52) 0.135 1.10(0.76–1.58) 0.621 0.49(0.20–1.24) 0.134
Quartile (Range, μM)
 Quartile 1 (4.45–27.9) 10(2.7) 364(3997) 1.19(0.47–3.00) 0.720 1.35(0.51–3.60) 0.546 1.39(0.51–3.79) 0.516
 Quartile 2 (27.9–37.5) 8(2.2) 363(4019) Reference   Reference   Reference  
 Quartile 3 (37.6–49.7) 11(3.0) 364(4036) 1.36(0.55–3.39) 0.509 1.21(0.46–3.18) 0.695 1.22(0.45–3.28) 0.695
 Quartile 4 (49.8–313) 10(2.7) 365(3982) 1.35(0.53–3.42) 0.529 1.10(0.37–3.24) 0.864 0.77(0.19–3.11) 0.711
Palmitelaidic acid (C16:1 t9), μM
Per unit increase 39(2.7) 1456 (16034) 1.05(0.97–1.13) 0.243 1.02(0.92–1.14) 0.707 1.01(0.86–1.18) 0.946
Per sd increase 1.19(0.89–1.58) 0.243 1.08(0.71–1.65) 0.707 1.02(0.55–1.88) 0.946
Quartile (Range, μM)
 Quartile 1 (1.1–5.1) 6(1.7) 363(3989) 0.65(0.24–1.74) 0.388 0.80(0.27–2.31) 0.675 0.84(0.28–2.52) 0.755
 Quartile 2 (5.1–6.8) 12(3.3) 365(4060) Reference   Reference   Reference  
 Quartile 3 (6.9–9.4) 8(2.2) 364(4057) 0.61(0.25–1.49) 0.280 0.54(0.21–1.38) 0.202 0.62(0.24–1.63) 0.334
 Quartile 4 (9.4–33.1) 13(3.6) 364(3928) 1.17(0.54–2.58) 0.688 1.09(0.39–3.03) 0.866 1.01(0.32–3.20) 0.987
Linolelaidic acid (C18:2 t9, 12), μM
Per unit increase 39(2.7) 1456 (16034) 1.04(0.85–1.27) 0.720 0.94(0.69–1.28) 0.705 0.74(0.50–1.11) 0.144
Per sd increase 1.06(0.77–1.46) 0.720 0.91(0.55–1.49) 0.705 0.62(0.33–1.17) 0.144
Quartile (Range, μM)
 Quartile 1 (0.7–2.0) 9(2.5) 364(3975) 1.18(0.47–2.99) 0.720 1.08(0.40–2.87) 0.880 1.19(0.44–3.24) 0.732
 Quartile 2 (2.0–2.7) 9(2.5) 363(4004) Reference   Reference   Reference  
 Quartile 3 (2.7–3.7) 10(2.7) 365(4057) 1.75(0.70–4.37) 0.230 1.48(0.55–3.95) 0.434 1.35(0.50–3.65) 0.553
 Quartile 4 (3.7–13.4) 11(3.0) 364(3998) 1.65(0.68–4.03) 0.271 1.31(0.47–3.65) 0.608 0.89(0.28–2.84) 0.844
  1. Model 1: adjusted for age, gender at baseline
  2. Model 2: further adjusted for race, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, total cholesterol, high density lipoprotein, uric acid, estimation glomerular filtration rate, alcohol use, smoking, and self-reported cardiovascular diseases history at baseline
  3. Model 3: further adjusted for other trans-fatty acid subtypes